We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation

Key Insights

• ANI Pharmaceuticals' Annual General Meeting to take place on 22nd of May
• Total pay for CEO Nikhil Lalwani includes US$794.9k salary
• Total compensation is similar to the industry average
• ANI Pharmaceuticals' total shareholder return over the past three years was 99% while its EPS grew by 83% over the past three years

We've discovered 1 warning sign about ANI Pharmaceuticals. View them for free.

We have been pretty impressed with the performance at ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) recently and CEO Nikhil Lalwani deserves a mention for their role in it. The pleasing results would be something shareholders would keep in mind at the upcoming AGM on 22nd of May. The focus will probably be on the future company strategy as shareholders cast their votes on resolutions such as executive remuneration and other matters. We think the CEO has done a pretty decent job and we discuss why the CEO compensation is appropriate.

View our latest analysis for ANI Pharmaceuticals

How Does Total Compensation For Nikhil Lalwani Compare With Other Companies In The Industry?

Our data indicates that ANI Pharmaceuticals, Inc. has a market capitalization of US$1.2b, and total annual CEO compensation was reported as US$8.9m for the year to December 2024. That's a notable increase of 9.7% on last year. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at US$795k.

For comparison, other companies in the American Pharmaceuticals industry with market capitalizations ranging between US$1.0b and US$3.2b had a median total CEO compensation of US$7.7m. From this we gather that Nikhil Lalwani is paid around the median for CEOs in the industry. Moreover, Nikhil Lalwani also holds US$28m worth of ANI Pharmaceuticals stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

Speaking on an industry level, nearly 26% of total compensation represents salary, while the remainder of 74% is other remuneration. ANI Pharmaceuticals pays a modest slice of remuneration through salary, as compared to the broader industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.

ANI Pharmaceuticals, Inc.'s Growth

ANI Pharmaceuticals, Inc.'s earnings per share (EPS) grew 83% per year over the last three years. It achieved revenue growth of 30% over the last year.

Shareholders would be glad to know that the company has improved itself over the last few years. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

Has ANI Pharmaceuticals, Inc. Been A Good Investment?

Most shareholders would probably be pleased with ANI Pharmaceuticals, Inc. for providing a total return of 99% over three years. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.

To Conclude...

Given the company's decent performance, the CEO remuneration policy might not be shareholders' central point of focus in the AGM. Instead, investors might be more interested in discussions that would help manage their longer-term growth expectations such as company business strategies and future growth potential.

While CEO pay is an important factor to be aware of, there are other areas that investors should be mindful of as well. That's why we did some digging and identified 1 warning sign for ANI Pharmaceuticals that you should be aware of before investing.

Switching gears from ANI Pharmaceuticals, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.